Jan van de Winkel, Genmab CEO
April 3, 2024 03:26 PM EDT
Deals
Pharma

Q&A: Gen­mab CEO on ink­ing the first ac­qui­si­tion in the com­pa­ny's 25-year his­to­ry

Kyle LaHucik

Senior Reporter

Gen­mab is an un­usu­al com­pa­ny in phar­ma. In 25 years, it has 44 INDs — 20 of those are still in clin­i­cal de­vel­op­ment — and eight mar­ket­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times